Serine peptidase inhibitor Kazal type 13 (SPINK13)

Serine peptidase inhibitor Kazal type 13 (SPINK13) is a secreted protein belonging to the Kazal-type serine protease inhibitor family. It is essential for sperm maturation and prevents premature acrosome reaction, thus playing a key role in male fertility[3][4]. SPINK13 directly inhibits serine-type endopeptidase activity, particularly targeting enzymes such as urokinase-type plasminogen activator (uPA). In oncology, SPINK13 is notable for its role as a tumor suppressor in hepatocellular carcinoma and clear cell renal cell carcinoma, exerting potent anti-proliferative effects by inactivating the PI3K/Akt pathway and inducing mitochondrial apoptosis in cancer cells[2][4]. It may also inhibit the activation of matrix metalloproteinases, thereby reducing tumor cell migration and invasion[2]. The protein is being explored as both a therapeutic drug candidate and a biomarker for several cancers, with ongoing studies investigating its post-translational modifications and folding for drug development[1][5]. SPINK13 shares sequence similarity and functional relationships with other Kazal-type inhibitors, such as SPINK1, SPINK2, and SPINK6, yet has unique tissue-specific expression and disease associations[4][6]. No FDA-approved drugs currently target SPINK13 directly, but it remains an active area of experimental research[2][5]. While therapeutic targeting is promising, broad inhibition of serine protease activity may entail safety risks related to impaired physiological regulation of proteases[2].

Other names

Serine protease inhibitor Kazal-type 13SPINK13HBVDNAPTP1SPINK5L3LiESP6HESPINTORMGC149260Hepatitis B virus DNA polymerase transactivated serine protease inhibitorHepatitis B Virus (HBV) DNA polymerase transactivated protein 1Hepatitis B virus DNA polymerase transactivated human serine protease inhibitorSerine protease inhibitor Kazal-type 5-like 3

Direct inhibition of urokinase-type plasminogen activator (uPA), thereby indirectly suppressing matrix metalloproteinase (MMP) activation. Inhibition of Furin protease activity. Downregulation of Notch1/Hes1/PTEN, leading to PI3K/Akt pathway inactivation, mitochondrial apoptosis, and cell cycle arrest in cancer models.